mRNA-1273 and BNT162b2 COVID-19 vaccines induce slightly different immune responses

mRNA-1273 and BNT162b2 COVID-19 vaccines induce slightly different immune responses

In a recent study published in the journal Science, researchers observed differential effector functions of antibodies elicited by Pfizer’s BNT162b2 and Moderna’s messenger ribonucleic acid (mRNA)-1273 coronavirus disease 2019 (COVID-19) vaccines.

​​​​​​​Study: mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. ​​​​​​​Image Credit: NIAID

Vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has greatly alleviated mortality and morbidity in regions with high vaccination coverage and remains the most effective tool for ending the COVID-19 pandemic. However, the recent global surge of COVID-19 infections soaring to new record highs has been concerning, given that the number of breakthrough cases is also rising.

Besides neutralizing and binding activities, antibodies mediate a host of immune functions recruiting several components of the immune system using the complement and fragment, crystallizable (Fc) receptors. Fc-mediated effector functions are implicated in protection against anthrax, influenza, human immunodeficiency virus (HIV), and more recently against SARS-CoV-2. Notably, these effector functions mediated by Fc receptors have been implicated in decreasing COVID-19 severity rather than transmission.

The study and findings

The present study evaluated and compared the humoral responses in a cohort of hospital workers who received the mRNA-1273 or BNT162b2 vaccines. Of the 73 participants, 45 were vaccinated with the BNT162b2 vaccine and 28 with the mRNA-1273 vaccine. Samples were collected 19 days post-second vaccination. Mild COVID-19 was documented before vaccination in 2% of BNT162b2 vaccinees and 7% of mRNA-127 vaccinees.

The authors investigated whether the Fc profiles were similar across the two subsets of participants. First, they analyzed the wild-type SARS-CoV-2 (D614G) receptor-binding domain (RBD)-, N-terminal domain (NTD)-, spike (S) protein-, S1- and S2-specific antibody titers, Fc receptor (FcR) binding, and Fc-mediated effector functions. The immune responses were robust across the two subsets of the cohort.

mRNA-1273 and BNT162b2 vaccines induce a comparable antibody profile across Alpha, Beta, and Gamma SARS-CoV-2 VOCs. (A and B) Univariate comparisons of (A) antibody titers and FcγR binding for SARS-CoV-2 Alpha, Beta, and Gamma VOCs as well as (B) ADCP and ADNP activity are shown for BNT162b2 (blue) and mRNA-1273 (red) vaccinated individuals. Vertical bars in (A) depict median values. Mann-Whitney U-tests corrected for multiple comparisons with the Benjamini-Hochberg (BH) method were used. Adjusted p-values are indicated as ***p < 0.001, **p < 0.01, and *p < 0.05. (C) A LASSO-PLSDA model is shown including all variant measurements. LASSO selected features were ranked based on their Variable of Importance (VIP) score, and the loadings of the latent variable 1 (LV1) were visualized in a bar graph. (D) A co-correlate network of the LASSO-selected features was built using a threshold of absolute Spearman rho greater than 0.7 and BH-adjusted p-value lower than 0.01. Nodes were colored based on the type of measurement; titers are shown in yellow, FcγRs are shown in green, and functional measurements are shown in gray. All shown links are positive correlations.

The univariate comparisons revealed equivalent immunoglobulins M and G (IgM and IgG) binding titers for both the sub-cohorts. The RBD-, spike-, NTD-, S1- domain-specific IgA binding titers were significantly higher in mRNA-1273 vaccinees. Moreover, the FcR binding was broadly equivalent across the sub-cohorts. Antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent complement deposition (ADCD) were similar across the two sub-cohorts at peak immunogenicity. On the contrary, antibody-dependent natural killer cell activation (ADNKA) and antibody-dependent neutrophil phagocytosis (ADNP) were elevated among the mRNA-1273 vaccinees.

Further, multivariate analyses were conducted to identify the vaccine-specific signatures, which revealed that overall, robust humoral responses were common to both the sub-cohorts; IgA immunity, NTD recognition, and specific antibody effector functions were enhanced in the mRNA-1273 vaccinees than in the BNT162b2 vaccinees.

Although the mRNA vaccines exhibit remarkable efficacy against SARS-CoV-2 D614G, several variants that compromise the neutralizing activity have appeared. The researchers noted that antibodies elicited by either mRNA vaccine were equally bound to Alpha, Beta, and Gamma variants of concern (VOCs). However, the IgM titers specific to the Beta and Gamma VOCs were elevated in the BNT162b2 recipients in contrast to the high IgA titers against the Alpha and Gamma VOCs in the mRNA-1273 vaccinees. Nonetheless, FcR binding was comparable across both the sub-cohorts for the three VOCs.

Next, antibody responses were profiled and compared across 16 mRNA-1273 vaccinees, 15 BNT162b2 vaccinees, and 10 convalescent persons. Vaccine-induced IgG1 and IgG3 responses were higher than the infection-acquired responses against D614G RBD and RBDs of all the tested VOCs (Alpha, Beta, Gamma, Kappa, and Delta); antibody binding to D614G RBD was superior compared to the VOC RBDs. The VOC-reactive antibodies elicited by the vaccines exhibited superior FcR binding than the infection-induced antibodies. The spike-specific IgG1 and IgG3 antibodies showed enhanced binding to full-length spike antigens from all the VOCs except the Kappa than the D614G variant. Interestingly, convalescent individuals had lower binding IgG responses specific to the spike protein than mRNA vaccinees indicating that FcR binding to full-length spike proteins was stable.

The research team depleted the RBD-specific antibodies from the polyclonal sera of vaccinees and convalescents to test antibody-mediated effector functions. The RBD antibody depletion reduced the ADCP activity against the spike proteins of the D614G, Alpha, Gamma, and Delta variants for the BNT162b2 vaccinees and convalescents.

Contrastingly, more variations were observed in ADNP activity in the convalescent persons for the Alpha, Beta, and Gamma VOCs. ADNKA activity was reduced in response to the spike protein of the Beta VOC in the BNT162b2 vaccinees. ADNKA activity was lost with RBD antibody depletion in convalescents against the D614G, Alpha, Gamma, and Delta spike proteins, but increased ADNKA activity was evident against the Beta spike protein.

Conclusions

In summary, the study probed the humoral responses elicited by two mRNA vaccines and observed distinct, robust Fc-functional responses by the vaccines indicating that the Fc-mediated effector responses could have a potential role in offering protection against disease caused by VOCs. Higher IgA titers, ADNP, and ACNKA activities were observed in mRNA-1273 vaccine recipients. RBD-specific antibody depletion had no significant effect on Fc-mediated effector functions among the vaccinees, while convalescent samples were affected by depleting RBD-specific antibodies. Overall, the depletion of RBD antibodies revealed the distinct roles of non-RBD effector functions, which might offer insights into the potential differences in immunity conferred by mRNA vaccines.

Journal reference:
  • mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions, P. Kaplonek et al., Sci. Transl. Med. 10.1126/scitranslmed.abm2311 (2022) DOI: 10.1126/scitranslmed.abm2311, https://www.science.org/doi/10.1126/scitranslmed.abm2311

Posted in: Medical Research News | Disease/Infection News | Pharmaceutical News

Tags: Anthrax, Antibody, Cell, Coronavirus Disease COVID-19, Efficacy, Fc receptor, HIV, Hospital, Immune Response, Immune System, immunity, Immunodeficiency, Influenza, Mortality, Pandemic, Phagocytosis, Protein, Receptor, Research, Respiratory, Ribonucleic Acid, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Spike Protein, Syndrome, Vaccine, Virus

Comments (0)

Written by

Tarun Sai Lomte

Tarun is a writer based in Hyderabad, India. He has a Master’s degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. He enjoys reading research papers and literature reviews and is passionate about writing.

Source: Read Full Article